Assessing the non-cancer risk for RDX (hexahydro-1,3,5-trinitro-1,3,5-triazine) using physiologically based pharmacokinetic (PBPK) modeling

Regulatory Toxicology and Pharmacology

Volumn 62, Issue 1, 2012, Pages 107-114

  Sweeney, Lisa M ^a   Gut, Chester P ^a   Gargas, Michael L ^a   Reddy, Gunda ^b   Williams, Larry R ^b   Johnson, Mark S ^b  

^a WRIGHT PATTERSON AIR FORCE BASE   (United States)

^b U S ARMY   (United States)

Author keywords

PBPK; Physiologically based pharmacokinetic model; RDX; Reference dose

Indexed keywords

CYCLONITE;

ABSORPTION; ARTICLE; BIOLOGICAL MODEL; CONCENTRATION RESPONSE; CONVULSION; DRUG EXPOSURE; HISTOPATHOLOGY; HUMAN; NEUROTOXICITY; NONHUMAN; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING; PREDICTION; PRIORITY JOURNAL; PROSTATITIS; RISK ASSESSMENT; RODENT; TREMOR;

ANIMALS; EXPLOSIVE AGENTS; HUMANS; MODELS, BIOLOGICAL; RISK ASSESSMENT; TRIAZINES;

ANIMALIA; RATTUS; RODENTIA;

EID: 84855514251     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2011.12.007     Document Type: Article

References (35)

1. Angerhofer, R.A., Lewis, B., Balezewski, L., 1986. Teratological Assessment of Trinitro-RDX in Rats. Study No. 75-51-0573-86. US Army Environmental Hygiene Agency, Aberdeen Proving Ground, MD. AD-A166 249.
2. Agency for Toxic Substances and Disease Registry (ATSDR), 1995. Toxicological Profile for RDX. US Department of Health and Human Services, Public Health Service.
3. ATSDR, 2010. Draft Toxicological Profile for RDX. US Department of Health and Human Services, Public Health Service. July 2010. Accessed October 13, 2010. http://www.atsdr.cdc.gov/toxprofiles/tp78.pdf.
4. Bannon D.I., Dillman J.F., Hable M.A., Phillips C.S., Perkins E.J. Global gene expression in rat brain and liver after oral exposure to the explosive hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX). Chem. Res. Toxicol. 2009, 22:620-625.
5. Bogdanffy M.S., Daston G., Faustman E.M., Kimmel C.A., Kimmel G.L., Seed J., Vu V. Harmonization of cancer and noncancer risk assessment: proceedings of a consensus-building workshop. Toxicol. Sci. 2001, 61:18-31.
6. Boobis A.R., Doe J.E., Heinrich-Hirsch B., Meek M.E., Munn S., Ruchirawat M., Schlatter J., Seed J., Vickers C. IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit. Rev. Toxicol. 2008, 38:87-96.
7. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 1997, 13:407-484.
8. Burdette L.J., Cook L.L., Dyer R.S. Convulsant properties of cyclotrimethylenetrinitramine (RDX): spontaneous audiogenic, and amygdaloid kindled seizure activity. Toxicol. Appl. Pharmacol. 1988, 92:436-444.
9. Cholakis, J.M., Wong, L.C.K., Van Goethem, D.L., Minor, J., Short, R., Sprinz, H., Ellis, H.V. III., 1980. Mammalian toxicological evaluation of RDX. Midwest Research Institute, Kansas City, Missouri. MRI Project No. 4513-B for US Army Medical Research and Development Command, Fort Detrick, MD. ADA092531.
10. Etnier E.L. Water quality criteria for hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX). Regul. Toxicol. Pharmacol. 1989, 9:147-157.
11. Gadagbui, B., Patterson, J., Rak, A., Kutzman, R.S., Reddy, G., Johnson, M.S., 2011. Development of a relative source contribution factor for drinking water criteria: the case of hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX). Human Ecol. Risk Assess. Accepted.
12. International Programme on Chemical Safety (IPCS), 2010. Characterization and application of physiologically based pharmacokinetic models in risk assessment. Harmonization Project Document No. 9. World Health Organization. Geneva, Swizterland.
13. Johnson M.S., Quinn M.J., Bazar M.A., Gust K.A., Escalon B.L., Perkins E.J. Subacute toxicity of oral 2,6-dinitrotoluene and 1,3,5-trinitro-1,3,5-triazine (RDX) exposure to the northern bobwhite (Colinus virginianus). Environ. Toxicol. Chem. 2007, 26:1481-1487.
14. Kirman C.R., Sweeney L.M., Meek M.E., Gargas M.L. Assessing the dose-dependency of allometric scaling performance using physiologically based pharmacokinetic modeling. Regul. Toxicol. Pharmacol. 2003, 38:345-367.
15. Kirman C.R., Sweeney L.M., Gargas M.L., Kinzell J.H. Evaluation of possible modes of action for acute effects of methyl iodide in laboratory animals. Inhal. Toxicol. 2009, 21:537-551.
16. Krishnan K., Crouse L.C., Bazar M.A., Major M.A., Reddy G. Physiologically based pharmacokinetic modeling of cyclotrimethylenetrinitramine in male rats. J. Appl. Toxicol. 2009, 29:629-637.
17. Lachenmeier D.W., Uebelacker M. Risk assessment of thujone in foods and medicines containing sage and wormwood - evidence for a need of regulatory changes?. Regul. Toxicol. Pharmacol. 2010, 58:437-443.
18. Levine, B.S., Furedi-Machacek, E.M., Rac, V.S., Gordon, D.E., Lish, P.M., 1983. Determination of the chronic mammalian toxicological effects of RDX: twenty-four month chronic toxicity/carcinogenicity study of hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) in Fischer 344 rats. Phase V. Vol. 1. Contract No. DAMD 17-79-C-9161. ADA160774. US Army Medical Research and Development Command. Chicago, IL, IIT Research Institute.
19. Lish, P.M., Levine, B.S., Furedi, E.M., Sagartz, J.M., Rac, V.S., 1984. Determination of the chronic mammalian toxicological effects of RDX: Twenty-four month chronic toxicity/carcinogenicity study of hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) in the B6C3F1 hybrid mouse. Final report. Phase VI, Vol. 1. Contract No. DAMD 17-79-C-9161. ADA 160774. US Army Medical Research and Development Command. Ft. Detrick, Frederick, MD.
20. Ozhan G., Topuz S., Alpertunga B. Determination of cyclonite (RDX) in human plasma by high-performance liquid chromatography. Farmaco 2003, 58:445-448.
21. Paquet L., Monteil-Rivera F., Hatzinger P.B., Fuller M.E., Hawari J. Analysis of the key intermediates of RDX (hexahydro-1,3,5-trinitro-1,3,5-triazine) in groundwater: occurrence, stability and preservation. J. Environ. Monit. 2011, 13:2304-2311.
22. Parker G.A., Reddy G., Major M.A. Reevaluation of a twenty-four-month chronic toxicity/carcinogenicity study of hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) in the B6C3F1 hybrid mouse. Int. J. Toxicol. 2006, 25:373-378.
23. Quinn M.J., McFarland C., Bazar M., Perkins E., Gust K., Johnson M.S. Sublethal effects of subacute exposure to RDX (1,3,5-trinitro-1,3,5-triazine) in the northern bobwhite (Colinus virginianus). Environ. Toxicol. Chem. 2009, 28:1266-1270.
24. Schneider N.R., Bradley S.L., Andersen M.E. Toxicology of cyclotrimethylenetrinitramine: distribution and metabolism in the rat and the miniature swine. Toxicol. Appl. Pharmacol. 1977, 39:531-541.
25. Simini M., Wentsel R.S., Checkai R.T., Phillips C.T., Chester N.A., Major M.A., Amos J.C. Evaluation of soil toxicity at Joliet Army Ammunition Plant. Environ. Toxicol. Chem. 1995, 14:623-630.
26. Talmage S.S., Opresko D.M., Maxwell C.J., Christopher J.E., Welsh F.M.C., Reno P.H., Daniel F.B. Nitroaromatic munition compounds: environmental effects and screening values. Rev. Environ. Contam. Toxicol. 1999, 161:1-156.
27. Testud F., Glanclaude J.-M., Descotes J. Acute hexogen poisoning after occupational exposure. Clin. Toxicol. 1996, 34:109-111.
28. Travis C.C. Tissue dosimetry for reactive metabolites. Risk Anal. 1990, 10:317-321.
29. US Army, 2006. Toxicology study No. 85-XC-5131-03. Subchronic oral toxicity of RDX in rats. US Army Center for Health Promotion and Preventive Medicine, Aberdeen Proving Ground, MD.
30. US EPA, 1993. Integrated Risk Information system (IRIS). Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX). Accessed on October 13, 2010. http://www.epa.gov/ncea/iris/subst/0313.htm.
31. US EPA, 2002. A review of the Reference Dose and Reference Concentration processes. EPA/630/P=-2/002F. Risk Assessment Forum, US EPA, Washington, DC.
32. US EPA, 2011. Recommended use of body weight 3/4 as the default method in derivation of the oral Reference Dose. EPA/100/R11/0001. Office of the Science Advisor, Risk Assessment Forum, US EPA, Washington, DC.
33. US Navy, 1974. Subacute toxicity of RDX and TNT in monkeys. Litton Bionetics, Contract No. N00014-73-C-0162. ADA044650. Office of Naval Research, Arlington, VA.
34. A receptor-mediated currents in the amygdala: a mechanism for RDX-induced seizures. Environ. Health Perspect. 2011, 119:357-363.
35. Woody R.C., Kearns G.L., Brewster M.A., Turley C.P., Sharp G.B., Lake R.S. The neurotoxicity of cyclotrimethylenetrinitramine (RDX) in a child: a clinical and pharmacokinetic evaluation. J. Toxicol. Clin. Toxicol. 1986, 24:305-319.